See the DrugPatentWatch profile for Saxenda
The National Drug Code (NDC) for Saxenda 18 mg 3 mL 5 pens is 50242-092-05 [1]. Saxenda is a brand-name prescription medication used for chronic weight management [2].
How is Saxenda administered?
Saxenda is administered as a once-daily injection [2]. Each pen contains 3 mL of the 18 mg/mL solution [1]. The pens are designed for single use [1].
What is the active ingredient in Saxenda?
The active ingredient in Saxenda is liraglutide [2]. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist [2].
What is liraglutide used for?
Liraglutide, the active ingredient in Saxenda, is used for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) who have at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia [2]. It is also used in conjunction with a reduced-calorie diet and increased physical activity [2].
When does Saxenda's patent expire?
Patent information for medications like Saxenda can be complex and may involve multiple patents covering the drug substance, formulations, and methods of use. For detailed and up-to-date patent expiration timelines, including those related to liraglutide and Saxenda, resources like DrugPatentWatch.com can provide specific data [3].
What are the risks associated with Saxenda?
Saxenda carries a boxed warning regarding the risk of thyroid C-cell tumors. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [2]. Other potential side effects include nausea, diarrhea, constipation, vomiting, abdominal pain, headache, and fatigue [2].
Are there alternatives to Saxenda for weight management?
Other medications approved for chronic weight management include semaglutide (Wegovy), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and orlistat (Xenical, Alli) [4]. Liraglutide is also available at a lower dose (0.6 mg, 1.2 mg, 1.8 mg) under the brand name Victoza for the treatment of type 2 diabetes [5].
Who manufactures Saxenda?
Saxenda is manufactured by Novo Nordisk [2].
Sources:
1. https://www.drugpatentwatch.com/product/saxenda-pens-50242-092-05
2. https://www.saxenda.com/
3. https://www.drugpatentwatch.com/
4. U.S. Food and Drug Administration. (2023, November 15). Weight Management Medications. Retrieved from https://www.fda.gov/consumers/consumer-updates/weight-management-medications
5. https://www.victoza.com/